Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors
Azitra, Inc. (AZTR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors Expanded eligibility significantly broadens potential treatment opportunities for ATR-04 beyond EGFR inhibitor-associated skin rash Add
- Product
- ATR04-484
- Indication
- rash associated with KRAS and MEK inhibitors
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The 8-K reports protocol amendments that broaden eligibility beyond EGFR inhibitor-associated rash to include KRAS and MEK inhibitor-associated rash, and NF1 patients with MEK-rash, alongside shorter washout periods to facilitate recruitment.
Market read
For AZTR, the key tradable takeaway is improved trial recruitment prospects via expanded eligibility and operational protocol changes, following advancement to Cohort 2.
What to watch
No new clinical data are disclosed; investors may need to wait for Cohort 2 safety/tolerability updates to validate that the expanded population responds similarly.
Background
Azitra’s ATR04-484 is a topical live biotherapeutic candidate being studied in a multicenter Phase 1/2 trial, with Cohort 2 expected to enroll about 24 patients after a safety review committee recommendation.
Ticker impact
Azitra amended its ATR-04 Phase 1/2 protocol to expand eligibility for rash from KRAS and MEK inhibitors, plus NF1 with MEK-rash, and shortened washout periods.
Likely modest upside bias as investors price improved probability of enrollment completion and continued progression to Cohort 2.
The filing is a primary clinical-trial protocol expansion with concrete operational changes (eligibility expansion, washout shortening) and links to Cohort 2 progression, but it does not provide new efficacy/safety results yet.
Market effects
Supports the precision dermatology and topical live biotherapeutic narrative by widening the addressable rash indications tied to targeted cancer therapies.
Limited, primarily affects US small-cap biotech sentiment.
Low, as the change is specific to a US clinical trial protocol and enrollment plan.
Counterpoint
Protocol expansion can increase heterogeneity of the patient population, potentially complicating safety signals or efficacy interpretation versus a narrower EGFR-rash cohort.
Key entities
- companyAzitra, Inc.
Clinical-stage biopharmaceutical company developing ATR04-484 for precision dermatology indications.
- product_candidateATR04-484
Topical live biotherapeutic product candidate being evaluated in Phase 1/2 for therapy-associated skin rashes.
- clinical_trialATR-04 Phase 1/2 clinical trial (NCT06830863)
Randomized, double-blind, vehicle-controlled study evaluating safety, tolerability, bioavailability, pharmacodynamics, and preliminary efficacy.

